GLP-1 Evidence

Artikel

GLP-1-lægemidler og knæartrose: hvad viste forsøget

Vægttab har altid været anbefalet ved knæartrose, og en lægemiddelklasse, der pålideligt giver et vægttab på 15-20% af kropsvægten, skulle uundgåeligt testes i denne sammenhæng. Nu er der gennemført ét forsøg. Her er, hvad det viste – og hvad det ikke viste.

Updated 3 min read 70 citations

Interiør af en ubenyttet indlæggelsesstue med seng, loftlift-skinne og sæder
Official Navy Page from United States of America MC2 Todd… · Public domain · Wikimedia Commons

Hvorfor spørgsmålet er relevant

Knæartrose er ikke rent mekanisk slid, men mekanisk belastning er en del af billedet, og mindre kropsvægt betyder mindre belastning på et vægtbærende led – en velkendt ortopædisk begrundelse snarere end et fund fra GLP-1-forsøgene. Fedme er også forbundet med artrose gennem metaboliske og inflammatoriske mekanismer, der går ud over simpel belastning – fedtvæv er metabolisk aktivt, og systemisk inflammation er en plausibel anden vej, hvorpå vægttab kan gavne led, der ikke bærer nogen vægt overhovedet, såsom hænderne. Et lægemiddel, der giver både betydeligt vægttab og, ifølge mekanistiske oversigter over lægemiddelklassen, ændringer i appetit- og energiregulering via centrale og perifere mekanismer, er en rimelig kandidat at teste [45].

Forsøget

Et randomiseret, placebokontrolleret forsøg testede semaglutid én gang om ugen specifikt hos personer med fedme og knæartrose [23]. Dette er en anden population og et andet primært endepunkt end de semaglutid- og tirzepatid-fedmeforsøg, der er beskrevet andre steder på dette site: de udfald, der blev målt her, var artrosesmerter og fysisk funktion, ikke kun vægt. Forsøget rapporterede en større forbedring i semaglutid-gruppen end i placebogruppen på både smerte- og funktionsmål, sammen med det vægttab, der konsekvent ses med dette lægemiddel i andre forsøg. Det er en genuint ny type resultat for denne lægemiddelklasse – et randomiseret forsøg med et ledspecifikt endepunkt, ikke en slutning draget fra vægttabsforsøg, der tilfældigvis spurgte om smerte som et sekundært mål.

Tre mekanismer, tre forskellige niveauer af evidens

MekanismeHvad understøtter detHvor solidt er det
Mindre mekanisk belastning fra vægttabVelkendt ortopædisk begrundelse for vægttab ved knæartrose genereltIkke et GLP-1-specifikt fund og uden for dette sites referencesæt
Direkte forsøgsevidens ved knæartroseÉt randomiseret, placebokontrolleret forsøg i netop denne population [23]Reelt, men et enkelt forsøg
Tab af ledstøttende muskulatur under behandlingData om kropssammensætning og fedtfri masse fra GLP-1-forsøg generelt [4] [8]Reelt, og virker i den modsatte retning

Den tredje række betyder noget og er let at overse i dækningen af dette forsøg. Fedtfri masse – herunder den muskulatur, der stabiliserer et knæled – udgør omkring en fjerdedel til en tredjedel af det vægttab, der ses med disse lægemidler, et fund, dette site behandler i detaljer på sin side om muskeltab. Artroseforsøgets nettoresultat var stadig positivt for smerte og funktion, hvilket betyder, at det muskeltab, der forekom, ikke opvejede fordelen ved den reducerede belastning og den mulige antiinflammatoriske effekt. Men det betyder, at den ærlige beskrivelse af dette lægemiddels effekt på et led er "nettoresultatet af to ting, der trækker i forskellige retninger," ikke blot "vægttab hjælper led."

Hvad forsøget ikke fortæller dig

Ét forsøg med ét lægemiddel, hos personer der havde fedme og diagnosticeret knæartrose ved inklusion, fastslår ikke en effekt for hele lægemiddelklassen, for andre led, for personer uden fedme eller for langsigtede strukturelle udfald som bruskvolumen. Det fortæller heller ikke, hvor varig fordelen er, efter lægemidlet er stoppet – et spørgsmål, som dette sites side om ophør allerede besvarer ugunstigt for selve vægten, og der findes ingen dedikerede opfølgningsdata for artrose, der kan sige, om lindring af ledsmerter følger samme mønster af tilbagegang.

Hvad dette betyder i praksis

Hvis knæsmerter og overvægt forekommer samtidig, er dette nu endnu et stykke evidens – et specifikt, randomiseret et – for, at vægttabet fra et GLP-1-lægemiddel kan omsættes til en målbar ledfordel, ikke blot et tal på vægten. Det er ikke evidens for, at disse lægemidler behandler artrose uafhængigt af vægttab, og det er ikke evidens for andre led eller andre populationer. Bivirkningsprofilen og spørgsmålet om muskeltab, som gælder for al brug af denne lægemiddelklasse, gælder også her; ingen af dem er anderledes, blot fordi måludfaldet er et led snarere end en taljemåling.

Ofte stillede spørgsmål

Behandler semaglutid artrose, eller hjælper det bare gennem vægttab?
Forsøget skelner ikke mellem de to. Det testede lægemidlet mod placebo og målte smerte og funktion, og det fandt en fordel; det testede ikke, om effekten findes uafhængigt af vægtændring [23].
Medfører lægemidlet specifikt muskeltab omkring knæet?
De publicerede data om kropssammensætning måler den samlede fedtfri masse, ikke muskulatur ved et specifikt led, så de kan ikke besvare det præcist – men de viser dog et betydeligt tab af fedtfri masse samlet set under behandlingen [4].
Var dette forsøg kun med semaglutid, eller gælder det også tirzepatide?
Kun semaglutid er hidtil blevet testet i denne specifikke population og med dette endepunkt. Tirzepatides større gennemsnitlige vægttab (se siden om tirzepatide) er et rimeligt grundlag for at forvente en sammenlignelig eller større effekt, men det er ekstrapolation, ikke forsøgsevidens.
Hvis jeg stopper lægemidlet, forsvinder ledfordelen så sammen med vægten?
Der findes ingen dedikerede langtidsopfølgningsdata om dette spørgsmål. I lyset af hvor konsekvent vægten vender tilbage efter ophør (se hvad der sker, når man stopper), ville det være rimeligt at forvente, at ledsymptomer følger vægten, men dette er ikke blevet målt direkte.
Løse runde tabletter præget med en identifikationskode, set fra oven
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

Relateret læsning

Evidensen bag denne side Et stablet søjlediagram, der viser sammensætningen af de 45 publikationer, der citeres på denne side, efter studietype. 16263meta-analysis (16)randomised trial (26)review (3)
45 publikationer, 2014–2026. Det er en blanding, der indeholder både studier og syntesestudier, hvilket er det udgangspunkt, hvorfra en påstand om årsag er rimelig. Kilde: denne sides egen citationsliste, nedenfor.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis Peng TR, Lin HH, Tseng TL, et al. · British journal of clinical pharmacology · 2026 · Meta-analysis DOIPubMed 42273973Full text
  2. Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis AbdelMagid AM, Kamel AM, Farid SF · Pharmacotherapy · 2026 · Meta-analysis DOIPubMed 41947610
  3. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  4. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials Ciudin A, Sapin H, Fan L, et al. · Advances in therapy · 2026 · Meta-analysis DOIPubMed 41820778Full text
  5. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis Naz F, Qaiser F, Mumtaz A, et al. · Medicine · 2026 · Meta-analysis DOIPubMed 42536519Full text
  6. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Eisa N, Barood O · Diabetes, obesity & metabolism · 2026 · Meta-analysis DOIPubMed 41877354
  7. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis Nong K, Shi Q, Xie X, et al. · BMJ (Clinical research ed.) · 2026 · Meta-analysis DOIPubMed 42419792
  8. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis Elganyny MKE, Elganyni AKE, Maskji HA, et al. · La Clinica terapeutica · 2026 · Meta-analysis DOIPubMed 42340790
  9. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  10. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  11. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  12. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  13. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  14. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration Khawaji A, A Jaly A, A Bakri H, et al. · Journal of obesity · 2025 · Meta-analysis DOIPubMed 40746703Full text
  15. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  16. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  17. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management Hiramoto B, McCarty TR, Lodhia NA, et al. · The American journal of gastroenterology · 2024 · Meta-analysis DOIPubMed 38634551Full text
  18. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  19. Weight loss efficiency and safety of tirzepatide: A Systematic review Lin F, Yu B, Ling B, et al. · PloS one · 2023 · Meta-analysis DOIPubMed 37141329Full text
  20. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  21. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  22. Anti-diabetic drugs and weight loss in patients with type 2 diabetes Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacological research · 2021 · Systematic review DOIPubMed 34302978
  23. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  24. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  25. A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism Johnson DA, Funnell MP, Cable TG, et al. · Appetite · 2026 · Randomised controlled trial DOIPubMed 41825697
  26. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  27. Effects of Sativex(®) Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial Bornæs O, Nielsen RL, Christensen LWS, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 42514343Full text
  28. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  29. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep medicine · 2025 · Randomised controlled trial DOIPubMed 41135142Full text
  30. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial Kadowaki T, Kiyosue A, Shingaki T, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40031941
  31. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40318682
  32. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  33. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Look M, Dunn JP, Kushner RF, et al. · Diabetes, obesity & metabolism · 2025 · Randomised controlled trial DOIPubMed 39996356Full text
  34. Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study Quast DR, Xie C, Bound MJ, et al. · Diabetes · 2025 · Randomised controlled trial DOIPubMed 39761379
  35. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) Agarwal R, Green JB, Heerspink HJL, et al. · Diabetes care · 2025 · Randomised controlled trial DOIPubMed 40968755Full text
  36. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  37. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  38. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, et al. · Molecular metabolism · 2023 · Randomised controlled trial DOIPubMed 37364710Full text
  39. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  40. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy) Yabe D, Kawamori D, Seino Y, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 36184780Full text
  41. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes Silver HJ, Olson D, Mayfield D, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 37188932Full text
  42. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023 · Randomised controlled trial DOIPubMed 36857477Full text
  43. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022 · Randomised controlled trial DOIPubMed 35015037Full text
  44. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  45. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  46. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  47. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  48. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  49. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Wharton S, Calanna S, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 34514682Full text
  50. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  51. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  52. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes] Scheen AJ, Radermecker RP, Paquot N · Revue medicale suisse · 2022 · Randomised controlled trial DOIPubMed 36004653
  53. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  54. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  55. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  56. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Frías JP, Auerbach P, Bajaj HS, et al. · The lancet. Diabetes & endocrinology · 2021 · Randomised controlled trial DOIPubMed 34293304
  57. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  58. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  59. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  60. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes Quast DR, Nauck MA, Schenker N, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 34189834
  61. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes care · 2020 · Randomised controlled trial DOIPubMed 32291277Full text
  62. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  63. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Sorli C, Harashima SI, Tsoukas GM, et al. · The lancet. Diabetes & endocrinology · 2017 · Randomised controlled trial DOIPubMed 28110911
  64. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  65. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016 · Randomised controlled trial DOIPubMed 27633186
  66. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. · Diabetes · 2014 · Randomised controlled trial DOIPubMed 25071023
  67. GLP-1 Receptor Agonists Rosen CJ, Ingelfinger JR · The New England journal of medicine · 2026 · Review DOIPubMed 41931049
  68. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance Bansal MB, Patton H, Morgan TR, et al. · Hepatology (Baltimore, Md.) · 2026 · Review DOIPubMed 41201884
  69. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Van Kleef LA, Michel M, Alkhouri N, et al. · Drug design, development and therapy · 2026 · Review DOIPubMed 41868171Full text
  70. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Moiz A, Filion KB, Tsoukas MA, et al. · The American journal of medicine · 2025 · Review DOIPubMed 39892489

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original